1. ALLA AKTIER
  2. NYHETER
  3. MENTICE

Mentice

Nyheter Mentice Nyheter alla bolag

Mentice publishes the company’s interim report for the period January – March 2023

MAR

Increased sales and positive EBITDA conclude a good start for 2023.

Significant events during the quarter

  • Two orders received from a large medical device company were announced during the quarter. The total value of these two orders together exceeded 13 MSEK.
  • Abbott Laboratories, together with Medtronic, were our largest clients in the quarter, with an order volume exceeding 17MSEK.
  • Alex Hussein was announced as our General Manager for the Americas region. Alex, prior to this position, held the position of Vice President of Sales for the Medical Device Industry USA, and he has been with Mentice since 2015.

FIRST QUARTER (JAN-MARCH 2023)

  • Order intake amounted to 57.7 (54.4) MSEK.
  • The order book by the end of the period was 126.2 (91.4) MSEK, whereof 66.2 MSEK is revenue expected in 2023.
  • Net sales amounted to 65.0 (53.1) MSEK, an increase of 22%, whereof 15% organic.
  • Earnings before interest, tax, depreciation, and amortization (EBITDA) totaled 7.3 (-1.3) MSEK.
  • Net income for the period amounted to -1.5 (-7.4) MSEK.
  • Earnings per share (EPS) were -0.06 (-0.30) SEK.
  • Cash flow from operating activities totaled 1.2 (11.2) MSEK.


Webcast presentation of the interim report
To join the presentation, please visit https://investor.mentice.com.

For more information, please contact:
Göran Malmberg, CEO, Mentice
E-post: goran.malmberg@mentice.com
US Mobile. +1 (312) 860 5610
Sweden Mobile +46 (0) 703 09 22 22

About Mentice
Mentice (STO: MNTC) is the world leader in proficiency based simulation solutions for image guided interventional therapies. Our solutions help healthcare professionals acquire, retain, and enhance their procedural skills driving improved productivity and outcomes. Mentice solutions are scientifically validated and have been specifically developed for healthcare providers and the medical device industry. Neurovascular, cardiovascular, and peripheral interventions are just some of the clinical areas covered by our solutions. Learn more about the features and benefits of Mentice solutions at: www.mentice.com

Marketplace| Nasdaq First North Growth Market, Stockholm | Ticker symbol MNTC
Certified Adviser| FNCA Sweden AB

This information is information that Mentice is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-04-27 08:30 CEST.

Attachments
Mentice Q1-2023 Interim Report EN

Datum 2023-04-27, kl 08:30
Källa MFN
Bifogade filer
Mentice Q1-2023 Interim Report EN
Affiliate
Investera som eToros bästa investerare! Med eToros CopyTrader™, kan du automatiskt kopiera andra investerares beslut. Hitta investerare som du tror på och kopiera deras investeringar i realtid. Inga extra avgifter tas ut för funktionen.
Copy Trading innebär inte investeringsrådgivning. Värdet på dina investeringar kan gå upp eller ner. Du riskerar ditt kapital.